Fortress Biotech Inc. reported its financial results for the second quarter ended June 30, 2025. The company achieved consolidated net revenue of $16.4 million, a rise from the $14.9 million recorded in the same quarter of 2024. The majority of this revenue was generated from marketed dermatology products. The company reported a significant turnaround in its financial performance, with a consolidated net income attributable to common stockholders of $13.4 million, translating to $0.50 per share basic, and $0.45 per share diluted. This marks a substantial improvement from a net loss of $(13.3) million, or $(0.73) per share basic and diluted, in the second quarter of 2024. In terms of expenses, consolidated research and development costs decreased to $8.1 million from $12.7 million in the prior year. However, consolidated selling, general and administrative expenses increased significantly to $38.8 million from $20.8 million in the same quarter of the previous year. Additionally, Fortress Biotech highlighted the acquisition of its subsidiary, Checkpoint Therapeutics, by Sun Pharma, with Fortress receiving approximately $28 million at closing. The company also announced the FDA's acceptance of a New Drug Application filing for the priority review of CUTX-101 to treat Menkes disease, with a PDUFA goal date of September 30, 2025. Furthermore, the commercial launch of Emrosi™ for treating inflammatory lesions of rosacea in adults has been initiated. As of June 30, 2025, Fortress' consolidated cash and cash equivalents totaled $74.4 million, reflecting an increase from $57.3 million as of December 31, 2024.